By: A. Decruyenaere MD, S. Rottey MD, PhD, D. De Maeseneer MD, T. Vermassen PhD
The 2022 annual ESMO meeting again offered striking presentations about the last trial updates in genitourinary cancers, including prostate, renal cell and urothelial cell carcinomas. This article will give an overview of the key highlights presented during this meeting in this setting.
(Belg J Med Oncol 2022;16(8):372–9)
* (only possible for healthcare professionals with RIZIV/INAMI/MATRICULE working in the field of Oncology/Hemato-oncology in Belgium and Luxembourg with prescription authorisation)
** (for healthcare professionals with prescribing authorisation working outside the field of Oncology/Hemato-oncology in Belgium and Luxembourg as well as those without prescribing authorisation working as healthcare professional in Oncology/Hemato-oncology in Belgium and Luxembourg, plus persons without prescription authorisation working outside Belgium and Luxembourg, plus healthcare professionals with prescribing authorisation outside Belgium and Luxembourg plus non-healthcare professionals from outside or inside Belgium or Luxembourg)
Top
